{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:21:16Z","timestamp":1788283276068,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2022xkj162"],"award-info":[{"award-number":["2022xkj162"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["202104j07020038"],"award-info":[{"award-number":["202104j07020038"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein & Peptide Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ppl.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:11:09Z","timestamp":1785942669000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4034-1294","authenticated-orcid":false,"given":"Menghuai","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhe","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ppl.2026.07.001_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.ppl.2026.07.001_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.ppl.2026.07.001_bib3","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.ppl.2026.07.001_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ppl.2026.07.001_bib5","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ppl.2026.07.001_bib6","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: Brentuximab vedotin in first-line treatment of peripheral T-Cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ppl.2026.07.001_bib7","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.7150\/thno.50564","article-title":"Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice","volume":"11","author":"Khan","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ppl.2026.07.001_bib8","first-page":"91","article-title":"Promotion of ovarian cancer cell invasion, migration and colony formation by the miR-21\/Wnt\/CD44v6 pathway","volume":"42","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.ppl.2026.07.001_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"20 Pt 1","key":"10.1016\/j.ppl.2026.07.001_bib10","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ppl.2026.07.001_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.radonc.2011.10.013","article-title":"Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control In vivo","volume":"102","author":"Gurtner","year":"2012","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.ppl.2026.07.001_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12943-025-02253-6","article-title":"Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"24","key":"10.1016\/j.ppl.2026.07.001_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ppl.2026.07.001_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e32801403f4","article-title":"Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study","volume":"18","author":"Rupp","year":"2007","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ppl.2026.07.001_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3389\/fimmu.2017.00956","article-title":"Development and characterization of a camelid single domain antibody-urease conjugate that targets vascular endothelial growth factor receptor 2","volume":"8","author":"Tian","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ppl.2026.07.001_bib16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.actbio.2022.01.037","article-title":"Anti-VEGFR2-labeled enzyme-immobilized metal-organic frameworks for tumor vasculature targeted catalytic therapy","volume":"141","author":"Zhou","year":"2022","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.ppl.2026.07.001_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"20","key":"10.1016\/j.ppl.2026.07.001_bib18","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ppl.2026.07.001_bib19","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ppl.2026.07.001_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/elsc.201900154","article-title":"Low-frequency mechanical vibration induces apoptosis of A431 epidermoid carcinoma cells","volume":"20","author":"Anggayasti","year":"2020","journal-title":"Eng. Life Sci."},{"issue":"1","key":"10.1016\/j.ppl.2026.07.001_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s40168-024-01907-9","article-title":"Tumor-colonized Streptococcus mutans metabolically reprograms tumor microenvironment and promotes oral squamous cell carcinoma","volume":"12","author":"Zhou","year":"2024","journal-title":"Microbiome"},{"issue":"10","key":"10.1016\/j.ppl.2026.07.001_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41419-024-07178-4","article-title":"Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK\/ERK pathway","volume":"15","author":"Feng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ppl.2026.07.001_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101932","article-title":"Exosomal miR-155 from M1-polarized macrophages promotes EndoMT and impairs mitochondrial function via activating NF-\u03baB signaling pathway in vascular endothelial cells after traumatic spinal cord injury","volume":"41","author":"Ge","year":"2021","journal-title":"Redox Biol."},{"issue":"20","key":"10.1016\/j.ppl.2026.07.001_bib24","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5706","key":"10.1016\/j.ppl.2026.07.001_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ppl.2026.07.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ppl.2026.07.001_bib27","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ppl.2026.07.001_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222280","article-title":"[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model","volume":"14","author":"Iwata","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ppl.2026.07.001_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)"}],"container-title":["Protein & Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929866526000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929866526000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:05:34Z","timestamp":1788282334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929866526000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0929866526000019"],"URL":"https:\/\/doi.org\/10.1016\/j.ppl.2026.07.001","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy","name":"articletitle","label":"Article Title"},{"value":"Protein & Peptide Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ppl.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}